Viskase Holdings, Inc. income statement VISK

Annual Quarterly

It recorded a net loss of $3.4 million. Diluted earnings per share were -$0.07. Over the twelve months ended Sep 30, 2026, revenue was $271.9 million and net income was $25.3 million. Across the 8 fiscal years shown, revenue shrank from $8.4 million in fiscal 2016 to $26,000 in fiscal 2024, about 56.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
272
—
0
+0.0%
—
0
-96.3%
1
+1248.1%
0
-74.9%
0
-97.0%
7
-17.4%
8
+0.0%
8
-52.0%
Operating income
11
+142.8%
-5
-300.2%
-1
-27.1%
-1
-1.2%
-1
-120.0%
-0
+64.1%
-1
—
—
—
—
Pretax income
11
+135.8%
-3
-401.3%
1
-7.6%
1
+415.3%
-0
+16.5%
-0
+64.6%
-1
-34.0%
-1
-116.6%
6
-16.5%
7
+5.5%
7
-38.5%
Income tax
-14
-190.8%
0
-94.5%
0
+322.4%
-0
+22.0%
-0
-2957.1%
0
+0.0%
0
+16.7%
0
+0.0%
0
-99.6%
2
-79.9%
8
+171.7%
Net income
25
+153.9%
-3
-538.2%
1
-43.3%
1
+838.2%
-0
+60.3%
-0
+64.2%
-1
-33.9%
-1
-116.7%
6
+7.4%
5
+583.6%
-1
-105.2%
Net income to common
23
+149.7%
-6
-1013.3%
-0
-607.1%
0
+106.7%
-1
+41.4%
-2
-40.7%
-2
—
—
5
+583.6%
-1
-105.2%
Basic EPS
0.29
+114.2%
-0.07
-600.0%
-0.01
0.00
+100.0%
-0.02
+33.3%
-0.03
—
—
—
0.12
+500.0%
-0.03
-106.1%
Diluted EPS
0.29
+114.2%
-0.07
-600.0%
-0.01
0.00
+100.0%
-0.02
+33.3%
-0.03
—
—
—
0.12
+500.0%
-0.03
-106.1%
Weighted average shares, basic
79
+249.8%
74
+0.0%
74
+0.0%
74
+0.0%
74
+99900.0%
0
—
—
—
44
+0.0%
44
+0.0%
Weighted average shares, diluted
79
+249.8%
74
+0.0%
74
+0.0%
74
+0.0%
74
+99900.0%
0
—
—
—
44
+0.0%
44
-0.0%
Margins
Operating margin
4.16%
—
-5,103.85%
—
-3,969.23%
-66.90%
-2,509.62%
—
—
—
—
Pretax margin
4.18%
—
4,326.92%
—
-1,484.62%
-65.91%
-2,507.69%
-470.05%
84.63%
83.64%
79.31%
Profit margin
9.29%
—
2,992.31%
—
-715.38%
-66.90%
-2,521.15%
-472.95%
84.55%
64.98%
-13.44%
Effective tax rate
-121.45%
—
30.84%
-12.82%
—
—
—
—
0.10%
22.30%
116.95%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
VISK (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Lombard, IL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
727510
Former names
ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.